Clinical Trials Browser

NIH × Lapatinib × Breast × Clear all

NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase 3 Completed

305 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01622868 2023-10-17

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

Phase 2 Completed

143 enrolled 24 charts

Brain Neoplasms, Breast Neoplasms

NCT00684983 2020-03-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Phase 2 Completed

64 enrolled 13 charts

Insulin-Like Growth Factor I, Resistance To, Breast Neoplasms

NCT00390455 2019-12-20

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Phase 3 Completed

295 enrolled 18 charts

Breast Neoplasms

NCT01434303 2019-05-20

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

Phase 1 Completed

Breast Neoplasms

NCT00555152 2018-04-20

Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ

Phase NA Completed

22 enrolled 9 charts

Carcinoma, Intraductal, Noninfiltrating

NCT00118157 2017-12-04

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Phase 2 Completed

19 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01688609 2017-09-11

Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer

Phase 2 Completed

18 enrolled 7 charts

Breast Neoplasms

NCT01245205 2014-10-23

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Phase 1 Terminated

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male

NCT00688194 2013-08-26

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

Phase 3 Unknown

Breast Neoplasms

NCT00098605 2013-06-06

Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases

Phase 2 Completed

Brain Neoplasms, Breast Neoplasms, Breast Neoplasms, Male